Pavlos Msaouel (@PavlosMsaouel) / X

Pavlos Msaouel

25.9K posts

Pavlos Msaouel

@PavlosMsaouel

Physician-Scientist, Oncologist, PI #MsaouelLab @MDAndersonNews | Tweets=my views | #kidneycancer #RenalMedullaryCarcinoma #endRMC #rarecancers

Houston, TX

faculty.mdanderson.org/profiles/pavlo…

Born January 19

Joined June 2017

Pinned
Pavlos Msaouel
@PavlosMsaouel
Jul 2, 2025
🚀 Now enrolling @MDAndersonnews: IVORY trial of #ivonescimab (first-in-class PD1×VEGF bispecific) in metastatic clear cell #KidneyCancer after prior IO±TKI. Hypothesis: cooperative inhibition of PD1/VEGF signaling will restore treatment sensitivity 👉 clinicaltrials.gov/study/NCT06940…
13K
Pavlos Msaouel
@PavlosMsaouel
Jun 11, 2022
1/4 New commentary on the big data paradox, i.e., the phenomenon whereby as the number of patients enrolled in a study *increases*, the probability that the confidence intervals from that study will include the truth *decreases* 👉 bit.ly/3xoEvP4
Pavlos Msaouel
@PavlosMsaouel
Sep 23, 2023
1/4 Just published our review on how to interpret RCTs focusing on key concepts such as sampling & allocation, uncertainty & variability, relevance & robustness, intention to treat & per protocol, potential outcomes & counterfactuals 👉 mdpi.com/2072-6694/15/1…
54K
Pavlos Msaouel
@PavlosMsaouel
May 2, 2020
1/13 A tweetorial on our @Cancer_Cell manuscript (bit.ly/2zHTfyj) on the genomic and immune hallmarks of #renalmedullarycarcinoma (RMC). @renalmedullary @RMCAwareness @RmcAlliance @kcCURE @DHealthhub @MDAndersonNews @chubbyemu @CancerMedMDA @KimrynRathmell #endRMC
Pavlos Msaouel
@PavlosMsaouel
Oct 19, 2023
The first #MsaouelLab R01 proposal scored well. Grateful to friends & mentors supporting our #RenalMedullaryCarcinoma research. Working non-stop to develop & open the 1st of the next generation of clinical trials within 2024 with more to come shortly after. #kidneycancer #endRMC
19K
Pavlos Msaouel
@PavlosMsaouel
May 1, 2024
Excited to publish @TheHDSR an overview on interpreting randomized controlled trials focusing on information. By prioritizing this fundamental principle, previously obscure statistical concepts reveal their intrinsic beauty: hdsr.mitpress.mit.edu/pub/yb9eq8ja/r…
37K
Pavlos Msaouel
@PavlosMsaouel
Dec 22, 2020
1/6 Excited to share our review article on the management of metastatic rare #kidneycancer subtypes: bit.ly/3mF95wv @KidneyCancer @kcCURE @IKCCorg @kidneycan @renalmedullary @RmcAlliance
Pavlos Msaouel
@PavlosMsaouel
May 16, 2023
Our latest #MsaouelLab collaboration with @LabGenovese @MDAndersonNews elucidates the connection between #SickleCellTrait and #SMARCB1 loss in #RenalMedullaryCarcinoma 👉pnas.org/doi/10.1073/pn…
41K
Pavlos Msaouel
@PavlosMsaouel
Apr 21, 2022
1/11 Just published in @ScienceTM our phase I-II trial of #sitravatinib in combination with #nivolumab in 42 immunotherapy-naïve patients with advanced clear cell #kidney cancer after progression on anti-VEGF TKIs 👉bit.ly/3jVQ0az
Pavlos Msaouel
@PavlosMsaouel
Nov 6, 2023
Receiving an award named after my friend and mentor @cgwoodMD is a tremendous honor that I will always treasure. He is greatly missed but his legacy carries on strong. Double bonus to receive it the year after another dear friend, @d_shapiro1!
Kidney Cancer
@KidneyCancer
Nov 6, 2023
We're proud to recognize three clinicians who are making a difference in #KidneyCancer with special career awards during #IKCSNA23! Thank you! ⭐ Dr. Nizar Tannir ⭐ @PavlosMsaouel ⭐ @uretericbud Read more: bit.ly/3SmY46F @MDAndersonNews @FoxChaseCancer
40K
Pavlos Msaouel
@PavlosMsaouel
Mar 1, 2021
1/30 Excited to share our #preprint identifying high-intensity (but not moderate-intensity) exercise as a modifiable risk factor for #renalmedullarycarcinoma (RMC) in the setting of #SickleCellTrait. bit.ly/3szoYbh 👇
Pavlos Msaouel
@PavlosMsaouel
May 10, 2023
1/6 Our newest #MsaouelLab paper reports on the efficacy, safety, and translational correlatives of neoadjuvant #sitravatinib monotherapy lead-in followed by the addition of #nivolumab in clear cell #kidney cancer nature.com/articles/s4146…
20K
Pavlos Msaouel
@PavlosMsaouel
Aug 14, 2022
1/5 Our just published paper aims to integrate selection diagrams with traditional biostatistics and the potential outcomes notation to coherently inform clinical decisions using the adjuvant therapy of #kidneycancer as our motivating example 👉 bit.ly/3wrbF15
Pavlos Msaouel
@PavlosMsaouel
Mar 12, 2024
Hazard ratio = 0.62 is a 38% decrease in hazard and *not* risk. When hazards are converted to probabilities (risks) then the improvement in risk practically never reaches 20%, much less 38%. These important decision-making nuances are explained here:
mdpi.com
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical...
We argue that well-informed patient-specific decision-making may be carried out as three consecutive tasks: (1) estimating key parameters of a statistical model, (2) using prognostic information to...
51K